EDAP TMS Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

EDAP TMS şirketinin kazançları yıllık ortalama -68.3% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 12% oranında artan oldu. Gelirler yıllık ortalama 9.4% oranında artan oldu.

Anahtar bilgiler

-68.3%

Kazanç büyüme oranı

-66.3%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	8.9%
Gelir büyüme oranı	9.4%
Özkaynak getirisi	-51.9%
Net Marj	-34.9%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

Oct 24

Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch

Sep 07

Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)

Jul 24

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

Mar 22

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

Aug 24

EDAP's Focal One Revenue Is Set To Accelerate

Aug 08

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

Jul 19

Acceleration At EDAP

Jan 11

EDAP TMS (NASDAQ:EDAP) Could Easily Take On More Debt

Jan 06

The Consensus EPS Estimates For EDAP TMS S.A. (NASDAQ:EDAP) Just Fell A Lot

Nov 25

EDAP's HIFU Progress Is Obscured By The Pandemic, But It's Real

Sep 07

EDAP's subsidiary names medTech industry veteran Ryan Rhodes as CEO

Jun 15

EDAP TMS S.A. (NASDAQ:EDAP) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Apr 02

Analysts Are Betting On EDAP TMS S.A. (NASDAQ:EDAP) With A Big Upgrade This Week

Jan 24

Treatment with EDAP's HIFU ultrasound benefits in prostate cancer patients, study shows

Jan 14

New reimbursement rules for HIFU technology to favor EDAP TMS

Dec 09

EDAP TMS S.A. EPS misses by $0.02, beats on revenue

Nov 18

Gelir ve Gider Dağılımı

EDAP TMS nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:EDAP Gelir, gider ve kazançlar (EUR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	63	-22	35	8
30 Jun 24	62	-20	34	8
31 Mar 24	61	-18	32	8
31 Dec 23	60	-21	34	7
30 Sep 23	57	-21	35	6
30 Jun 23	57	-17	33	6
31 Mar 23	57	-11	30	5
31 Dec 22	55	-3	24	5
30 Sep 22	53	4	21	4
30 Jun 22	51	3	20	4
31 Mar 22	47	0	18	4
31 Dec 21	44	1	17	3
30 Sep 21	45	0	15	4
30 Jun 21	45	0	14	4
31 Mar 21	44	0	13	4
31 Dec 20	42	-2	14	4
30 Sep 20	38	-3	14	4
30 Jun 20	39	-2	14	4
31 Mar 20	42	0	15	4
31 Dec 19	45	2	15	4
30 Sep 19	46	4	15	4
30 Jun 19	44	2	15	4
31 Mar 19	40	0	14	4
31 Dec 18	39	0	14	4
30 Sep 18	36	-1	13	4
30 Jun 18	35	-1	13	4
31 Mar 18	36	-2	13	4
31 Dec 17	36	-1	13	4
30 Sep 17	36	-2	13	4
30 Jun 17	37	0	13	4
31 Mar 17	36	4	12	4
31 Dec 16	36	4	12	4
30 Sep 16	37	10	12	3
30 Jun 16	35	4	11	3
31 Mar 16	35	2	11	3
31 Dec 15	32	-2	11	3
30 Sep 15	27	-9	10	3
30 Jun 15	27	2	10	3
31 Mar 15	25	-4	10	3
31 Dec 14	26	-1	10	3
30 Sep 14	28	2	10	3
30 Jun 14	27	-5	9	3
31 Mar 14	26	0	9	2
31 Dec 13	24	-5	9	3

Kaliteli Kazançlar: EDAP şu anda kârlı değil.

Büyüyen Kar Marjı: EDAP şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: EDAP kârlı değildir ve zararlar son 5 yılda yılda 68.3% oranında artmıştır.

Büyüme Hızlandırma: EDAP 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: EDAP kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 10.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: EDAP hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -51.87% ) sahiptir.

EDAP TMS Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

EDAP TMS S.A. to Report Q3, 2024 Results on Nov 07, 2024

EDAP TMS S.A. to Report Q2, 2024 Results on Aug 28, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

Recent updates

EDAP TMS S.A. to Report Q3, 2024 Results on Nov 07, 2024

Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?

EDAP TMS S.A. Announces First Patients Treated in Phase I/Ii Study Evaluating Focal One Robotic Hifu for the Treatment of Benign Prostatic Hyperplasia (Bph)

Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch

EDAP TMS S.A. Announces Resignation of Marc Oczachowski as Chairman of Board of Directors, Effective September 30, 2024

EDAP TMS S.A. to Report Q2, 2024 Results on Aug 28, 2024

Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Announces Interim Results from Phase 3 Study Evaluating Robotic Hifu for the Treatment of Deep Infiltrating Endometriosis

EDAP TMS S.A. Appoints Fran Schulz to Board of Directors

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 35%, revenue upgraded

EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump

EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024

EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis

Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?

EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis

It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)

EDAP TMS S.A. Appoints Francois Dietsch as Global Chief Accounting Officer

Less than half of directors are independent

EDAP TMS S.A. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

EDAP TMS S.A. Announces Board Changes

New major risk - Revenue and earnings growth

EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023

Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)

Insufficient new directors

EDAP TMS S.A., Annual General Meeting, Jun 30, 2023

Consensus EPS estimates fall by 199%

Price target increased by 9.1% to US$15.00

First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022)

EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023

Price target increased by 12% to US$14.50

Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021)

Consensus EPS estimates increase by 36%

EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis

Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?

Now 20% undervalued

EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis

EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals

Consensus EPS estimates have been upgraded

Third quarter 2022 earnings released: EPS: €0 (vs €0.03 loss in 3Q 2021)

Now -35% undervalued

EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

EDAP TMS stock falls 7% aftermarket on proposed ADS offering

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M

EDAP's Focal One Revenue Is Set To Accelerate

EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022

Is EDAP TMS (NASDAQ:EDAP) Weighed On By Its Debt Load?

EDAP TMS S.A., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022

EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association

Price target decreased to US$12.00

Consensus EPS estimates have been downgraded.

Full year 2021 earnings: EPS and revenues miss analyst expectations

EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022